Estimaciones de analistas de Wall Street para MacroGenics, Inc. (MGNX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 12 |
| Mantener | 9 |
| Venta | 1 |
| Venta fuerte | 0 |
| Analistas totales | 22 |
| Calificación media (1-5) | 0.50 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.10 | ||
| 2026-08-13 | $0.31 | $-0.08 | +498.2% |
| 2026-05-13 | $-0.58 | $-0.57 | -1.8% |
| 2026-03-09 | $-0.22 | $-0.42 | +47.6% |
| 2025-11-12 | $0.27 | $-0.48 | +156.2% |
| 2025-08-14 | $-0.57 | $-0.59 | +3.4% |
| 2025-05-13 | $-0.65 | $-0.61 | -6.6% |
| 2025-03-20 | $-0.25 | $-0.23 | -8.7% |
Ratios de valoración
| Precio / Valor contable | 6.05 |
| EV / EBITDA | -2.46 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $86.6M | $155.5M | $60.1M | $62.0M | $97.8M | $75.6M | $150.0M | $57.2M | $148.3M | $149.5M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | $2.7M | $7.4M | $8.2M | $12.3M | $43.2M |
| Beneficio Bruto | $86.6M | $155.5M | $60.1M | $62.0M | $97.8M | $73.0M | $142.6M | $49.0M | $136.0M | $106.3M |
| I+D | $122.1M | $147.2M | $190.8M | $195.3M | $193.2M | $214.6M | $207.0M | $166.6M | $177.2M | $140.0M |
| Generales y Administrativos | $29.8M | $32.7M | $40.5M | $46.1M | $42.7M | $63.0M | $58.9M | $52.2M | $71.0M | $39.2M |
| Gastos Operativos | $146.6M | $177.7M | $231.3M | $239.2M | $228.8M | $275.8M | $264.1M | $217.2M | $246.6M | $179.2M |
| Beneficio Operativo | -$60.0M | -$22.1M | -$171.2M | -$177.2M | -$131.1M | -$202.8M | -$121.4M | -$168.2M | -$110.6M | -$72.8M |
| EBITDA | -$52.4M | -$14.9M | -$162.0M | -$164.9M | -$119.1M | -$190.9M | -$107.9M | $2.0M | -$57.4M | -$59.6M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.4M | $1.1M | $8.5M |
| Beneficio Antes de Impuestos | -$58.5M | -$19.6M | -$171.5M | -$151.8M | -$129.7M | -$202.1M | -$119.8M | -$9.1M | -$66.0M | -$75.3M |
| Impuestos | 0 | 0 | -$247000 | 0 | 0 | 0 | 0 | 0 | $944000 | -$672000 |
| Beneficio Neto | -$58.5M | -$19.6M | -$171.5M | -$151.8M | -$129.7M | -$202.1M | -$119.8M | -$9.1M | -$67.0M | -$74.6M |
| BPA | $-1.69 | $-0.54 | $-4.19 | $-3.16 | $-2.47 | $-3.37 | $-1.95 | $-0.15 | $-1.07 | $-1.18 |
| BPA Diluido | $-1.69 | $-0.54 | $-4.19 | $-3.16 | $-2.47 | $-3.37 | $-1.95 | $-0.15 | $-1.07 | $-1.18 |
| Acciones en Circulación (Diluidas) | $34.7M | $36.1M | $40.9M | $48.1M | $52.4M | $59.9M | $61.4M | $61.9M | $62.6M | $63.2M |
Precio
| Precio | $4.08 |
| Capitalización | $259M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: CLNN · CNTB · CNTX · COYA · IFRX · ORMP · OVID
Explorar sector: Healthcare · Biotechnology
Más secciones de MGNX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones